Chimerigen

CD279 [PD-1] (mouse):Fc (human) (rec.)

CHF 430.00
In stock
CHI-MF-111PD1-C100100 µgCHF 430.00
More Information
Product Details
Synonyms PD-1; Programmed Cell Death Protein 1; SLEB2
Product Type Protein
Properties
Source/Host HEK 293 cells
Sequence

The extracellular domain of mouse CD279 [PD-1] (aa 26-169) is fused to the Fc region of human IgG1.

Crossreactivity Mouse
MW ~42kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.06EU/μg purified protein (LAL test; Lonza).
Reconstitution Reconstitute with sterile water to a concentration of 100µl/ml.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Protein Negative Control

Fc (human) IgG1 Control (rec.)

Other Product Data

NCBI reference NP_032824.1: CD279 (mouse)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

CD279 (Programmed Cell Death Protein 1; PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-γ. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.